Study Title | PCYC-1146-IM: Phase 1/2 Dose Finding and Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD) |
---|---|
Protocol ID | PCYC-1146-IM |
Disease (Sub Disease) | Chronic Graft Versus Host Disease |
Diagnosis Stage | New Diagnosis Relapse/Refractory |
Sponsor | Pharmacyclics LLC. |
Collaborators | Janssen Research & Development, LLC |
Links | https://clinicaltrials.gov/ct2/show/NCT03790332 |
Trial Status | Closed to Recruitment |
Trial Open Date | 22/01/2019 |
Study Type | Treatment |
Phase | Phase 1/2 |
Age Eligibility | Part A – 1 to 12 years Part B – 1 to 22 years |
International registry ID's | NCT03790332 |